Search 

PSites Pharma is developing the next generation of protein kinase inhibitors. Based on our discovery of a new non-ATP competitive, regulatory  binding site we had build up during the last 12 years a whole proprietary development platform, consisting of a focused library, a special screening and a crystallography platform. This allows us to develop clinical candidates for kinase inhibitors with specificities unknown for small coumpounds for any given ACG kinase target within 3 years.

Psites´s own lead compounds for oncology indications (lung and prostate cancer) had been successfully tested in mice and show a very good safety profile.

Our next financing round which is supported by a EUR 3 M. grant by the German governement will enable us to bring 2 compounds into the clinic and we are looking for partners who will share part of the development costs.

Alternatively we are also offering development collaborations for industrial partners who are interested in getting allosteric compounds for their specific target.

 

RECARDIO is an Austrian based life science company founded in 2011. It is focusing on regenerative therapeutic modalities for the treatment of cardiovascular diseases. After establishing proof-of-principle in vivo, it is developing multiple therapeutic leads as the future regenerative medication for patients with various cardiovascular diseases, with the potential of improving their cardiac function, quality of life and survival.  

Sanifit offers a new approach for calcification disorders. Sanifit´s lead Product (SNF472) for the reduction of calcification in dialysis patients is entering Phase I clinical trials. For the dental field OTC products were developed and are being out-licensed. The international management team has proven track record and long industry experience. Sanifit operates from Switzerland and Spain

Scancell is an AIM listed UK based company developing novel therapeutic vaccines for the treatment of cancer based on its groundbreaking ImmunoBody® and Moditope™ technology platforms. Scancell’s first cancer vaccine SCIB1 is a DNA vaccine being developed for the treatment of melanoma and is in Phase 2 clinical trials.

 

Treating cancer by vaccination allows small non-toxic doses of a vaccine to be administered to a patient, stimulating an immune response. Effective cancer vaccines need to target dendritic cells to stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

 

A limitation of many cancer vaccines currently in development is that they cannot specifically target dendritic cells in vivo. Several groups have demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing them with tumour antigens and re-infusing them. However, this procedure is patient specific, time consuming and expensive. Scancell has developed its breakthrough patent protected ImmunoBody® technology to overcome these limitations.

 

The Immunobody® technology can be adapted to provide the basis for treating any tumour type and may also be of potential utility in the development of vaccines against hepatitis, HIV and other chronic infectious diseases.

 

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity. The Moditope™ platform could have a profound effect on the way that cancer vaccines are developed.

Selcia Ltd., headquartered in Ongar, Essex, UK and with a branch in Hopkinton, Massachusetts, is a leading worldwide provider of contract research services. Selcia operates two divisions, Selcia Discovery and Selcia Radiochemistry. Whilst Radiochemistry specializes in 14C GMP radiolabelling, Selcia Discovery provides integrated small molecule drug discovery to pharmaceutical and biotech clients. Besides general medicinal chemistry and biology capabilities applicable across all target classes, Selcia Discovery has a particular strength in three unique and highly synergistic technologies: (1) medicinal chemistry on complex natural products, (2) capillary electrophoresis-based fragment and natural product screening, (3) peptidyl-prolyl isomerase targets (cyclophilins, FKBPs, Pin1, together called PPIases). Whilst relatively neglected by pharmaceutical companies in the past, understanding of the involvement of PPIases in many diseases is currently emerging. All PPIase inhibitors presently in clinical use or in development are natural products, natural product derivatives or have structures inspired by natural products.

The combination of these technologies has enabled Selcia to deliver several clinical PPIase inhibitors to clients, but has also generated IP for Selcia, which was recently demerged into a new company, Mitopharm Ltd. Mitopharm is in advanced license negotiations for a breakthrough drug in the field of acute and chronic neurodegenerative diseases. Other applications in the fields of chronic inflammatory diseases, oncology, COPD, and virus infections will be developed by Mitopharm either via investment or via joint R&D programs with pharmaceutical companies. 

Shield Therapeutics is an independent specialty pharmaceutical company, founded in 2008 with operations in Europe & US. Focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need Shield is led by Carl Sterritt, Chief Executive Officer, an experienced senior pharmaceutical executive with a track record of successful development and commercialisation of pharmaceuticals Shield has successfully raised ~$34m to fund the development of ST10 and PT20 (developed through Phosphate Therapeutics) Lead asset – ST10: Simplifying iron replacement therapy ·         Novel oral iron-based therapy with strong IPR ·         Potential to be the first simple effective oral therapy for the treatment of iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD) and non-dialysis dependant chronic kidney disease (CKD) ·         Currently in Phase III trials in patients with IDA in IBD ·         Results are expected to form the basis of a marketing authorisation application (“MAA”) in 2013.  If approved, product commercialisation could commence in 2014 ·         CKD-IDA trials to follow in 2012-2013 ·         Targets potential addressable market of $5bn, with immediate IV market currently reaching  >$1bn pa   PT20: for the treatment of hyperphosphataemia ·         Novel phosphate binder to treat hyperphosphataemia in patients with pre-dialysis and dialysis-dependent CKD ·         In-licensed from Medical Research Council - agreement signed in Q3-11 ·         Early data from in vitro and in vivo trials suggests higher specificity and efficacy than current market leaders and favourable opinion received from UK-MHRA for progression to Phase II clinical trials ·         Approximately 90% of patients with kidney failure require phosphate binder therapy at some point ·         Current market size >$1bn/yr  

SOM Biotech has developed a proprietary Drug Repurposing technology platform for discovery of new therapeutic indications for given drugs, which we are offering to partners for expanding their drug pipeline.

During the last 34 months we have validated 41 new indications, with 18 positive hits (43%), of which 3 cover clear medical need indications:

SOM0777 for the treatment of Glioma, already licensed to Argon Pharma and Draconis Pharma.

SOM0226 for the treatment of TTR-Amyloidosis. Orphan Disease. Phase II planned for 1Q 2013.

SOM0606 for the topical treatment of Psoriasis, in preclinical development. Phase II expected for 4Q 2013.

25 more repurposing programs per year are running to file the advanced company pipeline.